Skip to main content

Table 3 Number of patients included by trial type.

From: Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review

Cancer Type Studies Included Total Patients Number of Cetuximab Cetuximab with Pulmonary Reaction Number of Controls Controls with Pulmonary Reaction
  n n n n n n
Colorectal 23 3731 2227 76 (3.4) 1367 35 (2.6)
Head-Neck 10 1749 1004 173 (17.2) 516 104 (20.2)
Lung 10 1664 980 189 (19.6) † 671 82 (12.2)
Hepatobiliary/Pancreatic 5 209 167 9 (5.4) 42 0 (0.0)
Breast/Ovarian 3 78 78 10 (12.8) 0 0 (0.0)
Cutaneous 1 2 2 2 (100) 0 0 (0.0)
TOTAL: 52 7433 4458 459 (10.3) † 2596 221 (8.5)
  1. Patients were grouped into those who received cetuximab, either alone or in combination with other therapeutics, and controls (those who did not receive cetuximab). † p < 0.05 compared to control group. * One study contained patients with either Head-Neck or Non-small cell lung cancer and is displayed in both groups.